Anupriya Agarwal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anupriya Agarwal has a total of 294 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey W. Tyner
Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA
62 shared publications - Christopher A. Eide
Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, USA
50 shared publications - Stephen E. Kurtz
Division of Oncological Sciences, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR
50 shared publications - Nicola Long
Knight Cancer Institute, Oregon Health & Science University, Portland, OR
36 shared publications - Shannon K. McWeeney
Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
29 shared publications - Daniel Bottomly
Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA
28 shared publications
Latest Publications
- Open Access
- 9 March 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1659341
Targeting TLK2 with antisense oligonucleotides as a new strategy in acute myeloid leukemia
Introduction: Tousled-like kinase 2 (TLK2) is a serine/threonine kinase that plays a role in DNA replication, chromatin remodeling, and DNA damage response. TLK2 has been implicated in the pathogenesis of various types of cancer, including breast cancer, glioblastoma, and acute myeloid leukemia (AML). However, no potent and selective TLK2 inhibitors have been developed. Methods: We evaluated the efficacy of a human TLK2 antisense oligonucleotide (ASO) alone and in combination with gilteritinib in AML cell lines. To assess in vivo efficacy and toxicity, we administered a mouse TLK2 ASO alone or in combination with gilteritinib in a murine model of AML. Results: TLK2 ASO treatment resulted in a dose-dependent reduction of TLK2 mRNA levels and decreased cell viability in FLT3-mutant AML cell lines, with enhanced cytotoxicity observed when combined with gilteritinib. In a murine AML model, TLK2 ASO achieved approximately 50% knockdown efficiency. Both TLK2 ASO alone and in combination with gilteritinib significantly reduced spleen size, leukemia burden, and bone marrow progenitor cell populations. The treatment was generally well tolerated, with only minimal toxicity observed. Discussion: This study demonstrates that TLK2 ASO is a promising therapeutic strategy for AML, particularly in combination with FLT3 inhibition, and may apply to other TLK2-driven cancers. Future efforts should focus on improving ASO delivery and knockdown efficiency to maximize therapeutic benefit.
- 9 March 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1659341
Open AccessTargeting TLK2 with antisense oligonucleotides as a new strategy in acute myeloid leukemia
Introduction: Tousled-like kinase 2 (TLK2) is a serine/threonine kinase that plays a role in DNA replication, chromatin remodeling, and DNA damage response. TLK2 has been implicated in the pathogenesis of various types of cancer, including breast cancer, glioblastoma, and acute myeloid leukemia (AML). However, no potent and selective TLK2 inhibitors have been developed. Methods: We evaluated the efficacy of a human TLK2 antisense oligonucleotide (ASO) alone and in combination with gilteritinib in AML cell lines. To assess in vivo efficacy and toxicity, we administered a mouse TLK2 ASO alone or in combination with gilteritinib in a murine model of AML. Results: TLK2 ASO treatment resulted in a dose-dependent reduction of TLK2 mRNA levels and decreased cell viability in FLT3-mutant AML cell lines, with enhanced cytotoxicity observed when combined with gilteritinib. In a murine AML model, TLK2 ASO achieved approximately 50% knockdown efficiency. Both TLK2 ASO alone and in combination with gilteritinib significantly reduced spleen size, leukemia burden, and bone marrow progenitor cell populations. The treatment was generally well tolerated, with only minimal toxicity observed. Discussion: This study demonstrates that TLK2 ASO is a promising therapeutic strategy for AML, particularly in combination with FLT3 inhibition, and may apply to other TLK2-driven cancers. Future efforts should focus on improving ASO delivery and knockdown efficiency to maximize therapeutic benefit.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods_ Results from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Supplementary methods and Results description of Three-dimensional structural modeling of the CHEK2 protein
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods_ Results from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Supplementary methods and Results description of Three-dimensional structural modeling of the CHEK2 protein
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Supplementary Table S1 shows AML and MDS patients showing germline variants (pathogenic and likely pathogenic) in CHEK2 and description of their clinical characteristics.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Supplementary Table S1 shows AML and MDS patients showing germline variants (pathogenic and likely pathogenic) in CHEK2 and description of their clinical characteristics.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Data from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Background:Pathogenic (P) germline variants in CHEK2 are associated with a moderately increased risk of several solid tumors; however, their contribution to myeloid malignancies remains poorly defined.Methods:We analyzed germline CHEK2 variants in 1,035 patients with acute myeloid leukemia (AML) and 283 with myelodysplastic syndromes (MDS). P and likely pathogenic (LP) variants were identified, and their frequency, type, and clinical context were evaluated, including family and personal cancer histories.Results:P/LP CHEK2 variants were found in 1.74% of patients with AML and 1.77% of MDS cases. Although founder variants such as c.1100delC and p.I157T were present, most were rare missense variants with a population allele frequency below 0.001. These variants were significantly enriched in AML and MDS, even after adjusting for ethnicity. Notably, 39% of patients with AML with P/LP CHEK2 variants had a history of solid tumors or hematologic malignancies. Family history of cancer was also frequent, with 21% reporting hematologic and 57% reporting solid tumors.Conclusions:Our findings support an expanded role for germline CHEK2 variants in predisposing individuals to myeloid neoplasms, in addition to their association with solid tumor risk.Impact:Given the emerging evidence linking CHEK2 to clonal hematopoiesis (CH), these results underscore the need for prospective studies to refine risk assessment, inform genetic counseling, and guide surveillance strategies. These results suggest that clinical guidelines may consider monitoring CH in CHEK2 carriers and weigh the risks and benefits when considering CHEK2 carriers as stem cell transplant donors.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Background:Pathogenic (P) germline variants in CHEK2 are associated with a moderately increased risk of several solid tumors; however, their contribution to myeloid malignancies remains poorly defined.Methods:We analyzed germline CHEK2 variants in 1,035 patients with acute myeloid leukemia (AML) and 283 with myelodysplastic syndromes (MDS). P and likely pathogenic (LP) variants were identified, and their frequency, type, and clinical context were evaluated, including family and personal cancer histories.Results:P/LP CHEK2 variants were found in 1.74% of patients with AML and 1.77% of MDS cases. Although founder variants such as c.1100delC and p.I157T were present, most were rare missense variants with a population allele frequency below 0.001. These variants were significantly enriched in AML and MDS, even after adjusting for ethnicity. Notably, 39% of patients with AML with P/LP CHEK2 variants had a history of solid tumors or hematologic malignancies. Family history of cancer was also frequent, with 21% reporting hematologic and 57% reporting solid tumors.Conclusions:Our findings support an expanded role for germline CHEK2 variants in predisposing individuals to myeloid neoplasms, in addition to their association with solid tumor risk.Impact:Given the emerging evidence linking CHEK2 to clonal hematopoiesis (CH), these results underscore the need for prospective studies to refine risk assessment, inform genetic counseling, and guide surveillance strategies. These results suggest that clinical guidelines may consider monitoring CH in CHEK2 carriers and weigh the risks and benefits when considering CHEK2 carriers as stem cell transplant donors.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Supplementary Table S4 shows the Comparison of the somatic mutation frequencies between AML patients harboring CHEK2 P/LP germline variant and AML patients who had no P/LP germline variant identified
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Supplementary Table S4 shows the Comparison of the somatic mutation frequencies between AML patients harboring CHEK2 P/LP germline variant and AML patients who had no P/LP germline variant identified
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Supplementary Table S3 shows AML cohort used as control for no germline P/LP variants detected and their clinical characteristics
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Supplementary Table S3 shows AML cohort used as control for no germline P/LP variants detected and their clinical characteristics
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
List of tables and material included as supplemental information
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
List of tables and material included as supplemental information
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Supplementary Table S2 shows AML and MDS patients showing VUS germline variants in CHEK2 and their clinical characteristics.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Supplementary Table S2 shows AML and MDS patients showing VUS germline variants in CHEK2 and their clinical characteristics.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Figure S1 shows that Healthy control populations were matched to the AML and MDS patients in our cohort.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Figure S1 shows that Healthy control populations were matched to the AML and MDS patients in our cohort.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Supplementary Table S5 shows the odds of finding VUS variants in CHEK2 from AML and MDS patients versus control population
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Supplementary Table S5 shows the odds of finding VUS variants in CHEK2 from AML and MDS patients versus control population